Navigation Links
Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast
Date:10/18/2010

CINCINNATI, Oct. 18 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) announced today it will release its third quarter 2010 financial results after the market closes on Monday, Nov. 8, 2010. The Company will host a telephone conference call and simultaneous webcast on Tuesday, Nov. 9 at 8:30 a.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0709. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on Dec. 9, 2010, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit http://ir.kendle.com/phoenix.zhtml?p=irol-eventDetails&c=88712&eventID=3431689. Instructions for accessing the webcast are provided at the site. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Dec. 9, 2010.  Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
2. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
3. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
4. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
5. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
6. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Launches New Global Biostatistics Infrastructure
9. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
10. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
11. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot this ... of professional staff discussed strategies for preventing outbreaks among camp communities during the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... 27, 2017 , ... The respected dental team at Northwood ... without the extensive time commitment and aesthetic disadvantages of traditional braces can now ... custom-designed series of virtually invisible aligners are created for each patient and crafted ...
(Date:3/27/2017)... Plains, NY (PRWEB) , ... March 27, 2017 , ... ... Root Canal Awareness Week by teaching their patients about the key role this treatment ... therapy from an experienced endodontist. To better serve those who need a root ...
Breaking Medicine News(10 mins):